Recent derivatives from smaller classes of fermentation-derived antibacterials

Bibliography

• Boucher HW, Talbot GH, Bradley JS, Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Inf Dis 2009;48:1-12
   PubMed Web of Science ®Google Scholar
• Davies J, Davies G. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 2010;74:417-33
   PubMed Web of Science ®Google Scholar
• Kirst HA. Antibiotics versus resistant bacteria: a continual challenge. Expert Opin Ther Patents 2010;20:1271-2
   PubMed Web of Science ®Google Scholar
• Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science 2009;325:1089-93
   PubMed Web of Science ®Google Scholar
• Bush K. editor. Annals of the New York Academy of Sciences. Vol 1213. Antimicrobial Therapeutic Reviews. Blackwell Publishing; 2010
   Google Scholar
• Donadio S, Maffioli S, Monciardini P, Antibiotic discovery in the twenty-first century: current trends and future perspectives. J Antibiot 2010;63:423-30
   PubMed Web of Science ®Google Scholar
• Butler MS, Cooper MA. Antibiotics in the clinical pipeline in 2011. J Antibiot 2011;64:413-25
   PubMed Web of Science ®Google Scholar
• Demain AL, Sanchez S. Microbial drug discovery: 80 years of progress. J Antibiot 2009;62:5-16
   PubMed Web of Science ®Google Scholar
• Demain AL. Antibiotics: natural products essential to human health. Med Res Rev 2009;29:821-42
   PubMed Web of Science ®Google Scholar
• Omura S. Microbial metabolites: 45 years of wandering, wondering and discovering. Tetrahedron 2011;67:6420-59
   Web of Science ®Google Scholar
• Kavanagh F, Hervey A, Robbins WJ. Antibiotic substances from Basidiomyces. Proc Nat Acad Sci USA 1951;37:570-4
   PubMed Web of Science ®Google Scholar
• Phillips OA, Sharaf LH. Pleuromutilin antibacterial agents: patent review 2001-2006. Expert Opin Ther Patents 2007;17:429-35
   Web of Science ®Google Scholar
• Hu C, Zou Y. Mutilins derivatives: from veterinary to human-used antibiotics. Mini Rev Med Chem 2009;9:1397-406
   PubMed Web of Science ®Google Scholar
• Novak R, Shlaes DM. The pleuromutilin antibiotics: a new class for human use. Curr Opin Investig Drugs 2010;11:182-91
   PubMed Web of Science ®Google Scholar
• Islam KMS, Klein U, Burch DGS. The activity and compatibility of the antibiotic tiamulin with some other drugs in poultry medicine-a review. Poultr Sci 2009;88:2353-9
   PubMed Web of Science ®Google Scholar
• Weinberg JM, Tyring SK. Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus. J Drugs Dermatol 2010;9:1198-204
   PubMed Web of Science ®Google Scholar
• Yang LP, Keam SJ. Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs 2008;68:855-73
   PubMed Web of Science ®Google Scholar
• Rubino CM, Forrest A, Bhavnani SM, Population pharmacokinetics of BC-3781 using phase 1 data. 50th Intersci Conf Antimicrob Agents Chemother; Boston, MA; 2010. p. A1-018
   Google Scholar
• Wicha WW, Lell C, Logan DK, Prince WT. An age and gender study investigating the safety, tolerance and pharmacokinetics of BC-3781. 50th Intersci Conf Antimicrob Agents Chemother; Boston, MA; 2010. p. A1-019
   Google Scholar
• Sader HS, Farrell DJ, Biedenbach DJ, Jones RN. Antimicrobial activity of BC-3781, an investigational pleuromutilin, against organisms isolated from patients with CARTI and ABSSSI. 51st Intersci Conf Antimicrob Agents Chemother; Chicago, IL; 2011. p. C2-1798
   Google Scholar
• Diedenbach DJ, Jones RN, Ivezic-Schoenfeld Z, In vitro antibacterial spectrum of BC-3205, a novel pleuromutilin derivative for oral use in humans. 49th Intersci Conf Antimicrob Agents Chemother; San Francisco, CA; 2009. p. F1-1513
   Google Scholar
• Diedenbach DJ, Jones RN, Ivezic-Schoenfeld Z, In vitro antibacterial spectrum of BC-7013, a novel pleuromutilin derivative for topical use in humans. 49th Intersci Conf Antimicrob Agents Chemother; San Francisco, CA; 2009. p. F1-1521
   Google Scholar
• Nabriva Therapeutics. Pleuromutilin derivatives for the treatment of diseases mediated by microbes. WO2008113089; 2008
   Google Scholar
• Nabriva Therapeutics. Pleuromutilin derivatives containing a hydroxyamino or acyloxyaminocycloalkyl group. WO2007000004; 2007
   Google Scholar
• Nabriva Therapeutics. Process for the preparation of pleuromutilins. WO2008040043; 2008
   Google Scholar
• Nabriva Therapeutics. Pleuromutilin derivatives and their use as antimicrobials. WO2009009812; 2009
   Google Scholar
• Hirokawa Y, Kinoshita H, Tanaka T, Pleuromutilin derivatives having a purine ring. Part 1. Bioorg Med Chem Lett 2008;18:3556-61
   PubMed Web of Science ®Google Scholar
• Hirokawa Y, Kinoshita H, Tanaka T, Pleuromutilin derivatives having a purine ring. Part 2. Bioorg Med Chem Lett 2009;19:170-4
   PubMed Web of Science ®Google Scholar
• Hirokawa Y, Kinoshita H, Tanaka T, Pleuromutilin derivatives having a purine ring. Part 3. Bioorg Med Chem Lett 2009;19:175-9
   PubMed Web of Science ®Google Scholar
• Hirokawa Y, Kinoshita H, Tanaka T, Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens. J Med Chem 2008;51:1991-4
   PubMed Web of Science ®Google Scholar
• Dainippon Sumitomo Pharma. Novel mutilin derivatives. WO2008117796; 2008
   Google Scholar
• Dainippon Sumitomo Pharma. Mutilin derivative and pharmaceutical composition containing the same. WO2007037518; 2007
   Google Scholar
• Takadoi M, Sato T, Fukuda Y. Synthesis and antibacterial activity of novel C-12 substituted mutilins. 47th Intersci Conf Antimicrob Agents Chemother; Chicago, IL; 2007. p. F1-1696
   Google Scholar
• Kyorin Pharmaceutical Co. Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position. WO2008143343; 2008
   Google Scholar
• Kyorin Pharmaceutical Co. 12-position substituted mutilin derivative. WO2006070671; 2006
   Google Scholar
• Xu P, Zhang YY, Sun YX, Novel pleuromutilin derivatives with excellent antibacterial activity against Staphylococcus aureus. Chem Biol Drug Des 2009;73:655-60
   PubMed Web of Science ®Google Scholar
• Fu L, Jiang Z, Cai Z, Water-soluble phosphate prodrugs of pleuromutilin analogues with potent in vivo antibacterial activity against gram-positive pathogens. Bioorg Med Chem Lett 2009;19:5407-10
   PubMed Web of Science ®Google Scholar
• Shanghai Institute of Materia Medica. Pleuromutilin phosphate, its pharmaceutical composition, preparation method and uses thereof. WO2010028542; 2008
   Google Scholar
• Debono M, Barnhart M, Carrell CB, A21978C, a complex of new acidic peptide antibiotics. J Antibiot 1987;40:761-77
   PubMed Web of Science ®Google Scholar
• Kosmidis C, Levine DP. Daptomycin: pharmacology and clinical use. Expert Opin Pharmacother 2010;11:615-25
   PubMed Web of Science ®Google Scholar
• Baltz RH. Biosynthesis and genetic engineering of lipopeptide antibiotics related to daptomycin. Curr Top Med Chem 2008;8:618-38
   PubMed Web of Science ®Google Scholar
• Baltz RH. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr Opin Chem Biol 2009;13:144-51
   PubMed Web of Science ®Google Scholar
• Gu J-Q, Alexander DC, Rock J, Structural characterization of a lipopeptide antibiotic A54145E (Asn3Asp9) produced by a genetically engineered strain of Streptomyces fradiae. J Antibiot 2011;64:111-16
   PubMed Web of Science ®Google Scholar
• Yin N, He Y, Herradura P, Structure activity relationship studies of aromatic tail containing lipopeptides leading to CB-183,315, a novel cyclic lipopeptide being developed for the treatment of Clostridium difficile infection.. 50th Intersci Conf Antimicrob Agents Chemother; Boston, MA; 2010. p. F1-1612
   Google Scholar
• Cubist Pharmaceuticals. Novel antibacterial agents for the treatment of gram positive infections. WO2010075215; 2010
   Google Scholar
• Patino H, Stevens C, Louie T, Efficacy and safety of the lipopeptide CB-183,315 for the treatment of Clostridium difficile infection.. 51st Intersci Conf Antimicrob Agents Chemother; Chicago, IL; 2011. p. K-205a
   Google Scholar
• Alexander DC, Rock J, Gu J-Q, Production of novel lipopeptides related to A54145 by Streptomyces fradiae mutants blocked in biosynthesis of modified amino acids and assignment of IptJ, IptK and IptL gene functions. J Antibiot 2011;64:79-87
   PubMed Web of Science ®Google Scholar
• Nguyen KT, He X, Alexander DC, Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties. Antimicrob Agents Chemother 2010;54:1404-13
   PubMed Web of Science ®Google Scholar
• Pang WK, Cheng L, Parr I, Synthesis and biological activity of lysine derivatives of the lipopeptide A54145. 50th Intersci Conf Antimicrob Agents Chemother; Boston, MA; 2010. p. F1-2027
   Google Scholar
• Robbel L, Marahiel MA. Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery. J Biol Chem 2010;285:27501-8
   PubMed Web of Science ®Google Scholar
• Strieker M, Marahiel MA. The structural diversity of acidic lipopeptide antibiotics. ChemBioChem 2009;10:607-16
   PubMed Web of Science ®Google Scholar
• Baltz RH, Miao V, Wrigley SK. Natural products to drugs: daptomycin and related lipopeptide antibiotics. Nat Prod Rep 2005;22:717-41
   PubMed Web of Science ®Google Scholar
• Jerala R. Synthetic lipopeptides: a novel class of anti-infectives. Expert Opin Investig Drugs 2007;16:1159-69
   PubMed Web of Science ®Google Scholar
• Heinemann B, Kaplan MA, Muir RD, Hooper IR. Amphomycin, a new antibiotic. Antibiot Chemother 1953;3:1239-42
   Google Scholar
• Curran WV, Leese RA, Jarolmen H, Semisynthetic approaches to laspartomycin analogues. J Nat Prod 2007;70:447-50
   PubMed Web of Science ®Google Scholar
• Migenix Inc. Compositions of lipopeptide antibiotic derivatives and methods of use thereof. WO2005000878; 2005
   Google Scholar
• Pasetka CJ, Erfle DJ, Cameron DR, Novel antimicrobial peptides with long in vivo half-lives. Int J Antimicrob Agents 2010;35:182-5
   PubMed Web of Science ®Google Scholar
• Rubinchik E, Schneider T, Elliott M, Mechanism of action and limited cross-resistance of new lipopeptide MX-2401. Antimicrob Agents Chemother 2011;55:2743-54
   PubMed Web of Science ®Google Scholar
• Dugourd D, Yang H, Elliott M, Antimicrobial properties of MX-2401, an expanded spectrum lipopeptide active in the presence of lung surfactant. Antimicrob Agents Chemother 2011;55:3720-8
   PubMed Web of Science ®Google Scholar
• Available from: http://biotuesdays.com/wp-content/uploads/2010/07/BioWest-Product-Pipeline
   Google Scholar
• Ainsworth GC, Brown AM, Brownlee G. Aerosporin, an antibiotic produced by Bacillus aerosporus. Nature 1947;160:263
   Web of Science ®Google Scholar
• Molina J, Cordero E, Pachon J. New information about the polymyxin/colistin class of antibiotics. Expert Opin Pharmacother 2009;10:2811-28
   PubMed Web of Science ®Google Scholar
• Nation RL, Li J. Colistin in the 21st century. Curr Opin Inf Dis 2009;22:535-43
   PubMed Web of Science ®Google Scholar
• Velkov T, Thompson PE, Nation RL, Li J. Structure-activity relationships of polymyxin antibiotics. J Med Chem 2010;53:1898-916
   PubMed Web of Science ®Google Scholar
• BioSource Pharm, Inc. Peptide antibiotics and methods for making same. WO2006083317; 2006
   Google Scholar
• Keith DD, Borders D, Curran WV, Synthesis and activity of CB-182,804: a novel polymyxin analog active against clinically relevant gram-negative bacteria. 50th Intersci Conf Antimicrob Agents Chemother; Boston, MA; 2010. p. F1-1619
   Google Scholar
• Coleman S, Deats T, Pawliuk R, CB-182,804 is less nephrotoxic as compared to polymyxin B in monkeys following seven days of repeated intravenous dosing. 50th Intersci Conf Antimicrob Agents Chemother; Boston, MA; 2010. p. F1-1630
   Google Scholar
• BioSource Pharm, Inc. Antibiotic compositions for the treatment of gram-negative infections. WO2010075416; 2010
   Google Scholar
• Vaara M, Vaara T. Structure-activity studies on novel polymyxin derivatives that carry only three positive charges. Peptides 2010;31:2318-21
   PubMed Web of Science ®Google Scholar
• Vaara M. Polymyxins and their novel derivatives. Curr Opin Microbiol 2010;13:574-81
   PubMed Web of Science ®Google Scholar
• Northern Antibiotics. Polymyxin derivatives and uses thereof. WO2008017734; 2008
   Google Scholar
• Vaara M, Fox J, Loidl G, Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob Agents Chemother 2008;52:3229-36
   PubMed Web of Science ®Google Scholar
• Lundberg CV, Vaara T, Frimodt-Møller N, Vaara M. Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice. J Antimicrob Chemother 2010;65:981-5
   PubMed Web of Science ®Google Scholar
• Vaara M, Siikanen O, Apajalahti J, A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob Agents Chemother 2010;54:3341-6
   PubMed Web of Science ®Google Scholar
• Northern Antibiotics. Short fatty acid tail polymyxin derivatives and uses thereof. WO2009098357; 2009
   Google Scholar
• Mingeot-Leclercq M-P, Tulkens PM, Vaara T, Vaara M. Novel polymyxin derivatives are less cytotoxic than polymyxin B in a model of LLC-PK1 renal cell line. 51st Intersci Conf Antimicrob Agents Chemother; Chicago, IL; 2011. p. F2-170
   Google Scholar
• Okimura K, Ohki K, Sato Y, Chemical conversion of natural polymyxin B and colistin to their N-terminal derivatives. Bull Chem Soc Jpn 2007;80:543-52
   Web of Science ®Google Scholar
• Okimura K, Ohki K, Sato Y, Semi-synthesis of polymyxin B (2-10) and colistin (2-10) analogs employing the trichloroethoxycarbonyl (Troc) group for side chain protection of alpha,gamma-diaminobutyric acid residues. Chem Pharm Bull 2007;55:1724-30
   PubMed Web of Science ®Google Scholar
• Katsuma N, Sato Y, Ohki K, Development of des-fatty acyl-polymyxin B decapeptide analogs with Pseudomonas aeruginosa-specific antimicrobial activity. Chem Pharm Bull 2009;57:332-6
   PubMed Web of Science ®Google Scholar
• Sato Y, Shindo M, Sakura N, Novel des-fatty acid acyl-polymyxin B derivatives with Pseudomonas aeruginosa-specific antimicrobial activity. Chem Pharm Bull 2011;59:597-602
   PubMed Web of Science ®Google Scholar
• Hughes RA, Moody CJ. From amino acids to heteroaromatics—thiopeptide antibiotics, nature's heterocyclic peptides. Angew Chem Int Ed 2007;46:7930-54
   PubMed Web of Science ®Google Scholar
• Bagley MC, Dale JW, Merritt EA, Xiong X. Thiopeptide antibiotics. Chem Rev 2005;105:685-714
   PubMed Web of Science ®Google Scholar
• Pagano JF, Weinstein MJ, Stout HA, Donovick R. Thiostrepton, a new antibiotic. Antibiot Annu 1956;1955/1956:554-9
   Google Scholar
• Nicolaou KC, Zak M, Safina BS, Total synthesis of thiostrepton. Angew Chem Int Ed 2004;43:5092-7
   PubMedGoogle Scholar
• Astellas Pharma and Waseda University. Thiopeptide compound. WO2007049582; 2007
   Google Scholar
• Yamanouchi Pharmaceutical Co. Thiopeptide compounds. WO2002072617; 2002
   Google Scholar
• Meiji Seika Kaisha. Novel antibiotic SF2876 substance, process for production thereof, and pharmaceutical composition. WO2009119710; 2009
   Google Scholar
• Pang WK, Cheng L, Epie F, Nosiheptide analogs: synthesis and in vitro biological activity of novel semi-synthetic thiopeptide antibiotics. 50th Intersci Conf Antimicrob Agents Chemother; Boston, MA; 2010. p. F1-2099
   Google Scholar
• He Y, Wrona I, Li Q, Synthesis and structure-activity relationship (SAR) of thiopeptide GE37468A analogs at the pyrrolidine region with improved aqueous solubility. 50th Intersci Conf Antimicrob Agents Chemother; Boston, MA; 2010. p. F1-2100
   Google Scholar
• Li Q, Wrona I, Pang W, Thiopeptide GE37468A analogs with modifications of the bis-dehydroalanine (DHA) region. 50th Intersci Conf Antimicrob Agents Chemother; Boston, MA; 2010. p. F1-2101
   Google Scholar
• Mullin S, Leeds J, Sachdeva M, In vitro selection for decreased susceptibility to semi-synthetic thiopeptide inhibitors of EF-Tu. 50th Intersci Conf Antimicrob Agents Chemother; Boston, MA; 2010. p. F1-2103
   Google Scholar
• LaMarche MJ, Leeds J, Brewer J, Discovery of LFF471 as an investigational agent for Clostridium difficile infection. 51st Intersci Conf Antimicrob Agents Chemother; Chicago, IL; 2011. p. B-1196
   Google Scholar
• Li C, Kelly WL. Recent advances in thiopeptide antibiotic biosynthesis. Nat Prod Rep 2010;27:153-64
   PubMed Web of Science ®Google Scholar
• Arndt HD, Schoof S, Lu JY. Thiopeptide antibiotic biosynthesis. Angew Chem Int Ed 2009;48:6770-3
   PubMed Web of Science ®Google Scholar
• Liao R, Duan L, Lei C, Thiopeptide biosynthesis featuring ribosomally synthesized precursor peptides and conserved posttranslational modifications. Chem Biol 2009;16:141-7
   PubMed Web of Science ®Google Scholar
• Li C, Zhang F, Kelly WL. Heterologous production of thiostrepton A and biosynthetic engineering of thiostrepton analogs. Mol Biosyst 2011;7:82-90
   PubMedGoogle Scholar
• Novartis AG. Thiopeptide precursor protein, gene encoding it and uses thereof. WO2009019289; 2009
   Google Scholar
• Onaka H. Biosynthesis of indolocarbazole and goadsporin, two different heterocyclic antibiotics produced by actinomycetes. Biosci Biotechnol Biochem 2009;73:2149-55
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li Y, Chen D, Radical-mediated enzymatic carbon chain fragmentation-recombination. Nature Chem Biol 2011;7:154-60
   PubMed Web of Science ®Google Scholar
• Nicolaou KC, Zak M, Rahimipour S, Discovery of a biologically active thiostrepton fragment. J Am Chem Soc 2005;127:15042-4
   PubMed Web of Science ®Google Scholar
• Bower J, Drysdale M, Hebdon R, Structure-based design of agents targeting the bacterial ribosome. Bioorg Med Chem Lett 2003;13:2455-8
   PubMed Web of Science ®Google Scholar
• Baumann S, Schoof S, Harkal SD, Arndt HD. Mapping the binding site of thiopeptide antibiotics by proximity-induced covalent capture. J Am Chem Soc 2008;130:5664-6
   PubMed Web of Science ®Google Scholar
• Ross AC, Vederas JC. Fundamental functionality: recent developments in understanding the structure-activity relationships of lantibiotic peptides. J Antibiot 2011;64:27-34
   PubMed Web of Science ®Google Scholar
• Dawson MJ. Lantibiotics as antimicrobial agents. Expert Opin Ther Patents 2007;17:363-9
   Web of Science ®Google Scholar
• Lee H, Kim H-Y. Lantibiotics, class I bacteriocins from the genus Bacillus. J Microbiol Biotechnol 2011;21:229-35
   PubMed Web of Science ®Google Scholar
• Sentinella Pharmaceuticals. Lantibiotic carboxyamide derivatives with enhanced antibacterial activity. WO2010058238; 2010
   Google Scholar
• Sentinella Pharmaceuticals. Genes and proteins for the biosynthesis of the lantibiotic 107891. WO2009019524; 2009
   Google Scholar
• Novacta Biosystems. Actagardine derivatives, and pharmaceutical use thereof. WO2011095769; 2011
   Google Scholar
• Novacta Biosystems. Actagardine derivatives, and pharmaceutical use thereof. WO2010082019; 2010
   Google Scholar
• Novacta Biosystems. Lantibiotic-based compounds having antimicrobial activity. WO2009010765; 2009
   Google Scholar
• Novacta Biosystems. The use of type-B lantibiotic-based compounds having antimicrobial activity. WO2009010763; 2009
   Google Scholar
• Novacta Biosystems. Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. liguriae. WO2007083112; 2007
   Google Scholar
• Novacta Biosystems. Variants of the lantibiotic mersacidin and their use. WO2007036706; 2007
   Google Scholar
• Mothia B, Appleyard AN, Wadman S, Tabor AB. Synthesis of peptides containing lanthionine bridges on the solid phase: an analogue of rings D and E of the lantibiotic nisin. Org Lett 2011;13:4216-9
   PubMed Web of Science ®Google Scholar
• Deegan LH, Suda S, Lawton EM, Manipulation of charged residues within the two-peptide lantibiotic lacticin 3147. Microb Biotechnol 2010;3:222-34
   PubMedGoogle Scholar
• Sharma A, Khuller GK, Sharma S. Peptide deformylase – a promising therapeutic target for tuberculosis and antibacterial drug discovery. Expert Opin Ther Targets 2009;13:753-65
   PubMed Web of Science ®Google Scholar
• Leeds JA, Dean CR. Peptide deformylase as an antibacterial target: a critical assessment. Curr Opin Pharmacol 2006;6:445-52
   PubMed Web of Science ®Google Scholar
• Falconer SB, Brown ED. New screens and targets in antibacterial drug discovery. Curr Opin Microbiol 2009;12:497-504
   PubMed Web of Science ®Google Scholar
• Gordon JJ, Kelly BK, Miller GA. Actinonin: an antibiotic substance produced by an actinomycete. Nature 1962;195:701-2
   PubMed Web of Science ®Google Scholar
• Chen DZ, Patel DV, Hackbarth CJ, Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochem 2000;39:1256-62
   PubMed Web of Science ®Google Scholar
• Aubart K, Benowitz A, Campobasso N, Hydrazinopyrimidines as a new class of peptide deformylase inhibitors. 50th Intersci Conf Antimicrob Agents Chemother; Boston, MA; 2010. p. F1-2110
   Google Scholar
• Qin D, Fang Y, Benowitz A, Peptide deformylase inhibitors: discovery of a clinical candidate from a novel chemical class. 50th Intersci Conf Antimicrob Agents Chemother; Boston, MA; 2010. p. F1-2111
   Google Scholar
• GlaxoSmithKline LLC. Peptide deformylase inhibitors. WO2009061879; 2009
   Google Scholar
• Ma Z, Ginsberg AM, Spigelman M. Antimycobacterium agents. In: Taylor JB, Triggle DJ, editors. Comprehensive medicinal chemistry II. Volume 7 Elsevier; 2007. p. 699-709
   Google Scholar
• Van den Boogaard J, Kibiki GS, Kisanga ER, New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009;53:849-62
   PubMed Web of Science ®Google Scholar
• Mitnick CD, McGee B, Peloquin CA. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother 2009;10:381-401
   PubMed Web of Science ®Google Scholar
• Aristoff PA, Garcia GA, Kirchhoff PD, Hollis Showalter HD. Rifamycins – obstacles and opportunities. Tuberculosis (Edinb) 2010;90:94-118
   PubMed Web of Science ®Google Scholar
• Daley CL. Update in tuberculosis 2009. Am J Respir Crit Care Med 2010;181:550-5
   PubMed Web of Science ®Google Scholar
• Garey KW, Salazar M, Shah D, Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother 2008;42:827-35
   PubMed Web of Science ®Google Scholar
• Cumbre Pharmaceuticals. Quinolone carboxylic acid-substituted rifamycin derivatives. WO2009064792; 2009
   Google Scholar
• Robertson GT, Bonventre EJ, Doyle TB, In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:2313-23
   PubMed Web of Science ®Google Scholar
• Robertson GT, Bonventre EJ, Doyle TB, In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: Microbiology profiling studies with staphylococci and streptococci. Antimicrob Agents Chemother 2008;52:2324-34
   PubMed Web of Science ®Google Scholar
• Cumbre Pharmaceuticals. Nitroheteroaryl-containing rifamycin derivatives. WO2008008480; 2008
   Google Scholar
• Li J, Ma Z, Chapo K, Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins. Bioorg Med Chem Lett 2007;17:5510-13
   PubMed Web of Science ®Google Scholar
• Kim IH, Combrink KD, Ma Z, Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins. Bioorg Med Chem Lett 2007;17:1181-4
   PubMedGoogle Scholar
• Combrink KD, Denton DA, Harran S, New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases. Bioorg Med Chem Lett 2007;17:522-6
   PubMed Web of Science ®Google Scholar
• Activbiotics, Inc. Rifamycin analogs and uses thereof. WO2007070613; 2007
   Google Scholar
• Activbiotics, Inc. Rifamycin analogs and uses thereof. WO2007056086; 2007
   Google Scholar
• Rothstein DM, Mullin S, Sirokman K, Rifalazil and derivative compounds show potent efficacy in a mouse model of H. pylori colonization. J Antibiot 2008;61:485-8
   PubMed Web of Science ®Google Scholar
• Murphy CK, Karginova E, Sahm D, Rothstein DM. In vitro activity of novel rifamycins against gram-positive clinical isolates. J Antibiot 2007;60:572-6
   PubMed Web of Science ®Google Scholar
• Alfa Wassermann S.p.a. Rifamycin derivatives. WO2010122436; 2010
   Google Scholar
• Janssen Pharmaceutica. 3-Hydrazone piperazinyl rifamycin derivatives useful as antimicrobial agents. WO2009137380; 2009
   Google Scholar
• Array Biopharma. Capreomycin derivatives and their use as antibacterials. WO2007130743; 2007
   Google Scholar
• Wisconsin Alumni Research Foundation. Heterologous production of capreomycin and generation of new capreomycin derivatives through metabolic engineering. WO2008141190; 2008
   Google Scholar
• Arcamone F, Penco S, Orezzi PG, Structure and synthesis of distamycin A. Nature 1964;203:1064-5
   PubMed Web of Science ®Google Scholar
• Baraldi PG, Bovero A, Fruttarolo F, DNA minor groove binders as potential antitumor and antimicrobial agents. Med Res Rev 2004;24:475-528
   PubMed Web of Science ®Google Scholar
• Cortesi R, Esposito E. Distamycins: strategies for possible enhancement of activity and specificity. Mini Rev Med Chem 2010;10:217-30
   PubMed Web of Science ®Google Scholar
• Hu W, Burli RW, Kaizerman JA, DNA binding ligands with improved in vitro and in vivo potency against drug-resistant Staphylococcus aureus. J Med Chem 2004;47:4352-5
   PubMed Web of Science ®Google Scholar
• Khalaf AI, Waigh RD, Drummond AJ, Distamycin analogues with enhanced lipophilicity: synthesis and antimicrobial activity. J Med Chem 2004;47:2133-56
   PubMed Web of Science ®Google Scholar
• Anthony NG, Breen D, Clarke J, Antimicrobial lexitropsins containing amide, amidine, and alkene linking groups. J Med Chem 2007;50:6116-25
   PubMed Web of Science ®Google Scholar
• Ravic M, Suckling C, Gemmell C, MGB-BP-3, a new class antibacterial agent, effective in the treatment of severe Clostridium difficile associated diarrhea in a hamster CDAD model. 51st Intersci Conf Antimicrob Agents Chemother; Chicago, IL; 2011. p. B-1196b
   Google Scholar
• Dini C. MraY inhibitors as novel antibacterial agents. Curr Top Med Chem 2005;5:1221-36
   PubMed Web of Science ®Google Scholar
• Winn M, Goss RJ, Kimura K, Bugg TD. Antimicrobial nucleoside antibiotics targeting cell wall assembly: recent advances in structure-function studies and nucleoside biosynthesis. Nat Prod Rep 2010;27:279-304
   PubMed Web of Science ®Google Scholar
• Ichikawa S, Matsuda A. Nucleoside natural products and related analogs with potential therapeutic properties as antibacterial and antiviral agents. Expert Opin Ther Patents 2007;17:487-98
   Web of Science ®Google Scholar
• Tanino T, Ichikawa S, Shiro M, Matsuda A. Total synthesis of (-)-muraymycin D2 and its epimer. J Org Chem 2010;75:1366-77
   PubMed Web of Science ®Google Scholar
• Tanino T, Hirano S, Ichikawa S, Matsuda A. Synthetic study of muraymycins using Ugi-four component reaction. Nucleic Acid Symp Ser 2008;52:557-8
   Google Scholar
• Spork AP, Ducho C. Novel 5'-deoxy nucleosyl amino acid scaffolds for the synthesis of muraymycin analogues. Org Biomol Chem 2010;8:2323-6
   PubMed Web of Science ®Google Scholar
• Shionogi & Co. Nucleoside-type antibiotic. WO2010098365; 2010
   Google Scholar
• Shionogi & Co. Nucleoside-type antibiotic derivative. WO2010101061; 2010
   Google Scholar
• Cheng L, Chen W, Zhai L, Identification of the gene cluster involved in muraymycin biosynthesis from Streptomyces sp. NRRL 30471. Mol Biosyst 2011;7:920-7
   PubMedGoogle Scholar
• Hirano S, Ichikawa S, Matsuda A. Structure-activity relationship of truncated analogs of caprazamycins as potential anti-tuberculosis agents. Bioorg Med Chem 2008;16:5123-33
   PubMed Web of Science ®Google Scholar
• Hirano S, Ichikawa S, Matsuda A. Synthesis of caprazamycin analogues and their structure-activity relationship for antibacterial activity. J Org Chem 2008;73:569-77
   PubMed Web of Science ®Google Scholar
• Microbial Chemistry Research Foundation and Meiji Seika Kaisha. Antibacterial agent and therapeutic agent for Johne's disease comprising the same. WO2008020560; 2008
   Google Scholar
• Hirano S, Ichikawa S, Matsuda A. Design and synthesis of diketopiperazine and acyclic analogs related to the caprazamycins and liposidomycins as potential antibacterial agents. Bioorg Med Chem 2008;16:428-36
   PubMed Web of Science ®Google Scholar
• Ii K, Ichikawa S, Al-Dabbagh B, Function-oriented synthesis of simplified caprazamycins: discovery of oxazolidine-containing uridine derivatives as antibacterial agents against drug-resistant bacteria. J Med Chem 2010;53:3793-813
   PubMed Web of Science ®Google Scholar
• Kaysser L, Lutsch L, Siebenberg S. Identification and manipulation of the caprazamycin gene cluster lead to new simplified liponucleoside antibiotics and give insights into the biosynthetic pathway. J Biol Chem 2009;284:14987-96
   PubMed Web of Science ®Google Scholar
• Kaysser L, Siebenberg S, Kammerer B. Analysis of the liposidomycin gene cluster leads to the identification of new caprazamycin derivatives. ChemBioChem 2010;11:191-6
   PubMed Web of Science ®Google Scholar
• Funabashi M, Yang Z, Nonaka K, An ATP-independent strategy for amide bond formation in antibiotic biosynthesis. Nat Chem Biol 2010;6:581-6
   PubMed Web of Science ®Google Scholar
• Hotoda H, Furukawa M, Daigo M, Synthesis and antimycobacterial activity of capuramycin analogues. Part 1. Bioorg Med Chem Lett 2003;13:2829-32
   PubMed Web of Science ®Google Scholar
• Hotoda H, Daigo M, Furukawa M, Synthesis and antimycobacterial activity of capuramycin analogues. Part 2. Bioorg Med Chem Lett 2003;13:2833-6
   PubMed Web of Science ®Google Scholar
• Sequella Inc. Compositions and methods comprising capuramycin analogues. WO2009136965; 2009
   Google Scholar
• Reddy VM, Einck L, Nacy CA. In vitro antimycobacterial activities of capuramycin analogues. Antimicrob Agents Chemother 2008;52:719-21
   PubMed Web of Science ®Google Scholar
• Nikonenko BV, Reddy VM, Protopopova M, Activity of SQ641, a capuramycin analog in a murine model of tubereculosis. Antimicrob Agents Chemother 2009;53:3138-9
   PubMed Web of Science ®Google Scholar
• Dubuisson T, Bogatcheva E, Krishnan MY, In vitro antimicrobial activities of capuramycin analogues against non-tuberculous mycobacteria. J Antimicrob Chemother 2010;65:2590-7
   PubMed Web of Science ®Google Scholar
• Bogatcheva E, Dubuisson T, Protopopova M, Chemical modification of capuramycins to enhance antibacterial activity. J Antimicrob Chemother 2011;66:578-87
   PubMed Web of Science ®Google Scholar
• Kurosu M, Li K, Crick DC. Concise synthesis of capuramycin. Org Lett 2009;11:2393-6
   PubMed Web of Science ®Google Scholar
• Available from: www.rib-x.com/research-discovery/publications-presentations.php#RX04
   Google Scholar
• Kanyo Z, Devivo M, Bhattacharjee A, Structural basis for the binding of RX-04, a novel broad spectrum antibacterial class, to bacterial ribosomes. 51st Intersci Conf Antimicrob Agents Chemother; Chicago, IL; 2011. p. F1-1842
   Google Scholar
• Takeuchi S, Hirayama K, Ueda K, Yonehara H. Blasticidin S, a new antibiotic. J Antibiot 1958;11:1-5
   PubMed Web of Science ®Google Scholar
• Kumasaka T, Yamamoto W, Furuichi M, Crystal structures of blasticidin S deaminase (BSD). J Biol Chem 2007;282:37103-11
   PubMed Web of Science ®Google Scholar
• Marra A, Bortolon E, Molstad D, Novel ribosome inhibitors are efficacious in a murine peritonitis model caused by different bacterial pathogens. 51st Intersci Conf Antimicrob Agents Chemother; Chicago, IL; 2011. p. F1-1854
   Google Scholar
• Rib-X Pharmaceuticals, Inc. Antimicrobial compounds and methods of making and using the same. WO2011047323; 2011
   Google Scholar
• Rib-X Pharmaceuticals, Inc. Antimicrobial compounds and methods of making and using the same. WO2011047320; 2011
   Google Scholar
• Rib-X Pharmaceuticals, Inc. Antimicrobial compounds and methods of making and using the same. WO2011047319; 2011
   Google Scholar
• Butler MS, Buss AD. Natural products–the future scaffolds for novel antibiotics? Biochem Pharmacol 2006;71:919-29
   PubMed Web of Science ®Google Scholar
• Grabowski K, Baringhaus K-H, Schneider G. Scaffold diversity of natural products: inspiration for combinatorial library design. Nat Prod Rep 2008;25:892-904
   PubMed Web of Science ®Google Scholar
• Cordier C, Morton D, Murrison S, Natural products as an inspiration in the diversity-oriented synthesis of bioactive compound libraries. Nat Prod Rep 2008;25:719-37
   PubMed Web of Science ®Google Scholar
• Rosen J, Gottfries J, Muresan S, Novel chemical space exploration via natural products. J Med Chem 2009;52:1953-62
   PubMed Web of Science ®Google Scholar
• Planson A-G, Carbonell P, Grigoras I, Faulon J-L. Engineering antibiotic production and overcoming bacterial resistance. Biotechnol J 2011;6:812-25
   PubMed Web of Science ®Google Scholar
• Freire-Moran L, Aronsson B, Manz C, Critical shortage of new antibiotics in development against multi-drug resistant bacteria-Time to react is now. Drug Resist Updat 2011;14:118-24
   PubMed Web of Science ®Google Scholar
• Coates ARM, Halls G, Hu Y. Novel classes of antibiotics or more of the same? Br J Pharmacol 2011;163:184-94
   PubMed Web of Science ®Google Scholar
• Hardesty JS, Juang P. Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection. Pharmacotherapy 2011;31:877-86
   PubMed Web of Science ®Google Scholar